Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

video

Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

sound

Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Persian Version

Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

View:

203
Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Download:

111
Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Cites:

Information Journal Paper

Title

Comparative Efficacy of Meloxicam and Placebo in Vasospasm of Patients with Subarachnoid Hemorrhage

Pages

  125-130

Abstract

 Cerebral vasospasm considered to be a serious cause of morbidity and mortality following Subarachnoid haemorrhage (SAH). Despite several available therapeutic options, current protocols do not prevent major consequences of vasospasm. Inflammation is believed to play an important role in post-haemorrhagic vasospasm. Meloxicam is a non-steroidal antiinflammatory drug. The aim of this study was to compare the efficacy of Meloxicam versus placebo on vasospasm in patients with SAH. In this randomized, double-blind, placebocontrolled trial, SAH patients randomly received 7. 5 mg Meloxicam or placebo twice daily for 7 days. End points were, middle cerebral artery velocity obtained with transcranial doppler, in-hospital mortality, hospital stay and discharge Glasgow Outcome Scale. Eighty-one patients enrolled in the study. (40 received Meloxicam, 41 received placebo). Baseline characteristics were similar between the groups. There were no differences in length of hospitalization (17. 4 ± 3. 1 vs 18. 6 ± 4. 2 days; p = 0. 145), in-hospital mortality rate (15 vs 22%; p-value=0. 569), or GOS (p = 0. 972) between the two groups. MCA velocity were slightly less in patients who had received Meloxicam, but not to a significant degree (p-value=0. 564(. No side effect has been detected for Meloxicam. This study did not prove Meloxicam efficacy in vasospasm of SAH patients. But it demonstrated that clinical trial of Meloxicam in these patients is feasible and probably safe. The effectiveness of Meloxicam on Cerebral vasospasm has to be studied in larger trials.

Cites

  • No record.

    • References

  • No record.

    • Cite

    APA: Copy

    GHODSI, SEYED MOHAMMAD, MOHEBBI, NIAYESH, NADERI, SOHEIL, Anbarloie, Mousareza, Aoude, Ahmad, & Habibi Pasdar, Seyed Sohail. (2015). Comparative Efficacy of Meloxicam and Placebo in Vasospasm of Patients with Subarachnoid Hemorrhage. IRANIAN JOURNAL OF PHARMACEUTICAL RESEARCH (IJPR), 14(1), 125-130. SID. https://sid.ir/paper/288523/en

    Vancouver: Copy

    GHODSI SEYED MOHAMMAD, MOHEBBI NIAYESH, NADERI SOHEIL, Anbarloie Mousareza, Aoude Ahmad, Habibi Pasdar Seyed Sohail. Comparative Efficacy of Meloxicam and Placebo in Vasospasm of Patients with Subarachnoid Hemorrhage. IRANIAN JOURNAL OF PHARMACEUTICAL RESEARCH (IJPR)[Internet]. 2015;14(1):125-130. Available from: https://sid.ir/paper/288523/en

    IEEE: Copy

    SEYED MOHAMMAD GHODSI, NIAYESH MOHEBBI, SOHEIL NADERI, Mousareza Anbarloie, Ahmad Aoude, and Seyed Sohail Habibi Pasdar, “Comparative Efficacy of Meloxicam and Placebo in Vasospasm of Patients with Subarachnoid Hemorrhage,” IRANIAN JOURNAL OF PHARMACEUTICAL RESEARCH (IJPR), vol. 14, no. 1, pp. 125–130, 2015, [Online]. Available: https://sid.ir/paper/288523/en

    Related Journal Papers

  • No record.

    • Related Seminar Papers

  • No record.

    • Related Plans

  • No record.

    • Recommended Workshops






    Move to top